Potassium Ion

Potassium Ion

SCHEMBL817853

CCCCC(CC)CC(CC(CC)CCCC)(C(=O)[O-])C(C(=O)[O-])S(=O)(=O)O.[K+].[K+]

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA

The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CA2 P00918 5/20 0.43
RECQL P46063 1/20 0.40
ALDH1A1 P00352 4/20 0.35
CYP3A4 P08684 6/20 0.34
TSHR P16473 5/20 0.34
TDP1 Q9NUW8 2/20 0.34
ATM Q13315 1/20 0.34
CA1 P00915 2/20 0.33
NFKB1 P19838 2/20 0.33
NPSR1 Q6W5P4 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9949600 0.97 CA2 (0.43) CA2RECQLALDH1A1CYP3A4TSHR
SCHEMBL51224 0.97 CA2 (0.45) CA2RECQLALDH1A1CYP3A4TSHR
Lithium Ion SCHEMBL20526054 0.97 CA2 (0.43) CA2RECQLALDH1A1CYP3A4TSHR
SCHEMBL2425803 0.97 CA2 (0.43) CA2RECQLALDH1A1CYP3A4TSHR
Silver SCHEMBL2027794 0.97 CA2 (0.43) CA2RECQLALDH1A1CYP3A4TSHR
SCHEMBL8903389 0.89 CYP3A4 (0.41) CA2RECQLCYP3A4TSHRCA1
SCHEMBL10932193 0.89 CA2 (0.40) CA2RECQLALDH1A1CYP3A4TSHR
SCHEMBL31061740 0.88 CA2 (0.46) CA2RECQLCYP3A4TSHRCA1
SCHEMBL29957551 0.86 CA2 (0.45) CA2RECQLALDH1A1CYP3A4TSHR
SCHEMBL21330553 0.86 CA2 (0.35) CA2RECQLALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010097643-A1 FORMULATION BASED ON MICRONIZED ZEOLITE, GREEN TEA EXTRACT, AND GENISTEIN AS A THERAPEUTIC AGENT FOR REDUCTION OF BODY WEIGHT AND CELLULITE NOVATECH ISTRAZIVANJE D.O.O. (HR) 2010-09-02 WO claimed
US-7758684-B2 Ink additive and ink using same NISSIN CHEMICAL INDUSTRY CO., LTD. (JP) 2010-07-20 US claimed
WO-2010018418-A1 FORMULATION BASED ON MICRONIZED CLINOPTILOLITE AS THERAPEUTIC AGENT PROVIDING HIGHLY BIOAVAILABLE SILICON NOVATECH D.O.O. (HR) 2010-02-18 WO claimed
US-20070283845-A1 Ink additive and ink using same NISSIN CHEMICAL INDUSTRY CO., LTD. (JP) 2007-12-13 US claimed
US-12528935-B2 Latex composition for dip molding and dip-molded article ZEON CORPORATION (JP) 2026-01-20 US disclosed
US-12486384-B2 Latex composition and dip-molded body ZEON CORPORATION (JP) 2025-12-02 US disclosed
US-12421375-B2 Latex composition for dip molding and dip-molded article ZEON CORPORATION (JP) 2025-09-23 US disclosed
US-20250019502-A1 PREPARING METHOD OF POLYMER POWDER FOR BINDER AND BINDER COMPOSITION KOREA KUMHO PETROCHEMICAL CO., LTD. (KR) 2025-01-16 US disclosed
EP-3543261-B1 SYNTHETIC POLYISOPRENE LATEX ZEON CORP (JP) 2023-09-06 EP disclosed
EP-3520750-B1 METHOD OF MANUFACTURING PACKAGE STRUCTURE ZEON CORP (JP) 2023-05-24 EP disclosed
US-20230151193-A1 LATEX COMPOSITION FOR DIP MOLDING AND DIP-MOLDED ARTICLE ZEON CORPORATION (JP) 2023-05-18 US disclosed
EP-3424984-B1 METHOD FOR MANUFACTURING POLYMER LATEX ZEON CORP (JP) 2023-04-19 EP disclosed
US-20030065015-A1 Novel quarternary ammonium compositions coupled with facilitating anions and their use in kits, as well as their use in preventing and treating certain conditions BACANER MARVIN B (US) 2003-04-03 US disclosed
US-6482811-B1 Bretylium compositions and kits, and their use in preventing and treating cardio-vascular conditions BACANER MARVIN B (US) 2002-11-19 US disclosed
EP-1140054-A2 BRETYLIUM COMPOSITIONS AND KITS, AND THEIR USE IN PREVENTING AND TREATING CARDIOVASCULAR CONDITIONS Bacaner, Marvin B. (US) 2001-10-10 EP disclosed
US-6261352-B1 BETAINE, SULFO ESTER THE PILOT INK CO., LTD. (JP) 2001-07-17 US disclosed
WO-2000040232-A2 BRETYLIUM COMPOSITIONS AND KITS, AND THEIR USE IN PREVENTING AND TREATING CARDIOVASCULAR CONDITIONS BACANER MARVIN B (US) 2000-07-13 WO disclosed
EP-0964036-A2 Water-based ball-point pen ink composition THE PILOT INK CO., LTD. (JP) 1999-12-15 EP disclosed
US-4051299-A ALKYLENE OXIDE ADDUCT EMULSIFIER, MONO- OR DI-ESTER OR OIL LUBRICANT FIBER INDUSTRIES INC. (US) 1977-09-27 US disclosed
US-3997450-A ALKYLENE OXIDE FINISHES FIBER INDUSTRIES, INC. (US) 1976-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12528935-B2 Latex composition for dip molding and dip-molded article GLO1, WDR1, PIM1 CA2 4331/4885RECQL 3021/4885ALDH1A1 597/4885
US-20030065015-A1 Novel quarternary ammonium compositions coupled with facilitating anions and their use in kits, as well as their use in preventing and treating certain conditions SLC10A1, ATP6V1B1, SLC7A1 CA2 128/4885RECQL 748/4885ALDH1A1 3341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.